Updated Jul 24, 2026
/Scribe shares surge in public market debut with Eli Lilly and Sanofi as backers/Verizon lifts guidance as international governments respond to new tariff policies/Lisata Therapeutics terminates $4-a-share Kuva Labs merger after financing failure/Sidus Space Names Alan Khalili CFO, Effective July 27/Intel shares fall as 25% revenue jump marks fastest growth since 2011/GrafTech posts $40 million Q2 loss as electrode pricing slides/Scribe shares surge in public market debut with Eli Lilly and Sanofi as backers/Verizon lifts guidance as international governments respond to new tariff policies/Lisata Therapeutics terminates $4-a-share Kuva Labs merger after financing failure/Sidus Space Names Alan Khalili CFO, Effective July 27/Intel shares fall as 25% revenue jump marks fastest growth since 2011/GrafTech posts $40 million Q2 loss as electrode pricing slides
NewsSOS
← NewswireMarkets

Lisata Therapeutics terminates $4-a-share Kuva Labs merger after financing failure

LIBERTY CORNER, N.J., July 24. A $2 million termination fee is now owed to Lisata Therapeutics, Inc. after Kuva Labs Inc. failed to close a $4.00-per-share tender offer for the biotech, the company disclosed in a Form 8-K filed with the Securities and Exchange Commission Thursday. Kuva Labs told Lisata it could not obtain sufficient financing, letting the offer expire without payment on July 20, 2026.

By Marcus Cole2 min readLSTA
Share

Key takeaways

  • Lisata Therapeutics terminated its merger agreement with Kuva Labs after Kuva failed to obtain sufficient financing to close a $4.00-per-share tender offer, which expired unpaid on July 20, 2026.
  • Kuva Labs now owes Lisata a $2,000,000 termination fee under the merger agreement's terms.
  • No tendered shares were accepted for payment, and all tendered shares are being returned to holders through depositary Equiniti Trust Company, LLC.
  • Lisata's Board of Directors plans to evaluate strategic alternatives including a reverse merger, other business combination, asset sales, and dissolution, with no timetable set.
  • Lisata reserves rights to pursue damages for Willful Breach and Enforcement Costs, though the 8-K cautions that collection is not guaranteed.

LIBERTY CORNER, N.J., July 24. A $2 million termination fee is now owed to Lisata Therapeutics, Inc. after Kuva Labs Inc. failed to close a $4.00-per-share tender offer for the biotech, the company disclosed in a Form 8-K filed with the Securities and Exchange Commission Thursday. Kuva Labs told Lisata it could not obtain sufficient financing, letting the offer expire without payment on July 20, 2026.

How the deal collapsed

The merger agreement, dated March 6, 2026, called for Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs, to acquire all outstanding shares of Lisata Therapeutics common stock through a tender offer at $4.00 per share in cash. Shareholders were also to receive one contingent value right per share, carrying up to $3.00 in additional cash payments tied to specific milestones.

The agreement was amended multiple times, with the company filing updated disclosures as recently as July 21, 2026. The offer period itself ended one minute after 11:59 p.m. New York City time on July 20, 2026. Kuva Labs and Kuva Acquisition Corp. did not accept any tendered shares for payment.

Kuva Labs has instructed Equiniti Trust Company, LLC, the depositary and paying agent for the offer, to return all tendered shares to their holders. Lisata terminated the agreement under Section 8.3(a) of the merger agreement.

Termination fee and legal exposure

Under the merger agreement's terms, Kuva Labs owes Lisata a $2,000,000 termination fee. Lisata also said it reserves all rights to pursue damages for Willful Breach and Enforcement Costs as defined in the agreement.

The 8-K includes a caveat: Lisata's financial resources may constrain its ability to pursue litigation, and Kuva Labs may lack sufficient assets to satisfy any judgment obtained. Collection is not guaranteed.

Board weighs strategic options

Lisata Therapeutics' Board of Directors plans to evaluate strategic alternatives to improve stockholder value. The options under review include a reverse merger, other business combination, asset sales, and dissolution. The company set no timetable and said it will not comment further unless the Board approves a course of action or disclosure is otherwise required.

David J. Mazzo, PhD, President and Chief Executive Officer of the Liberty Corner, N.J.-based company, signed the filing on July 24, 2026. Lisata shares trade on the Nasdaq Capital Market under the ticker LSTA. Shareholders who tendered shares into the offer will receive those shares back through Equiniti Trust Company.

Keep reading

All bulletins →
MarketsJuly 24, 2026

Scribe shares surge in public market debut with Eli Lilly and Sanofi as backers

NEW YORK, July 24. Shares of Scribe surged during the company's public market debut, the release shows. Scribe is backed by Eli Lilly (L

2 min read
MarketsJuly 24, 2026

Verizon lifts guidance as international governments respond to new tariff policies

NEW YORK, July 24. Verizon Communications raised its financial guidance, the company said, as [international governments moved to address](/news/u-s-iran-war-escalation-puts-investors-and-e

2 min read
MarketsJuly 24, 2026

Sidus Space Names Alan Khalili CFO, Effective July 27

CAPE CANAVERAL, Fla., July 24. Alan Khalili will become chief financial officer of Sidus Space, Inc. (NASDAQ: SIDU) on July 27, 2026, the company disclosed in an 8-K filing Thursday. Khalili succeeds John Burke, who held the interim CFO role during what Sidus called a transition

2 min read

Frequently asked

Why did the Lisata–Kuva Labs merger fall apart?

Kuva Labs told Lisata it could not obtain sufficient financing to fund the $4.00-per-share tender offer, so the offer expired without payment on July 20, 2026.

How much was the deal worth per share?

The tender offer was $4.00 per share in cash, plus one contingent value right per share carrying up to $3.00 in additional cash payments tied to specific milestones.

What happens to shareholders who tendered their shares?

No tendered shares were accepted for payment, and Kuva Labs instructed Equiniti Trust Company, LLC to return all tendered shares to their holders.

What is Lisata planning to do next?

Lisata's Board of Directors will evaluate strategic alternatives such as a reverse merger, other business combination, asset sales, or dissolution, with no timetable set.

Will Lisata be able to collect the termination fee?

Collection is not guaranteed; the 8-K notes that Lisata's financial resources may limit its ability to litigate and Kuva Labs may lack sufficient assets to satisfy any judgment.